Debate – Response Milestones that Matter in Chronic Myeloid Leukemia: MMR vs. CCyR

In the majority of patients with TKI-sensitive chronic phase chronic myeloid leukemia (CP-CML), achievement of optimal response milestones at different timepoints during the treatment course is associated with excellent long-term outcomes. Treatment-free remission (TFR) has become an important new goal in the management of CML and it should be discussed with appropriate patients who meet the strict eligibility criteria. In view of the ongoing evolution of treatment goals, response milestones must be interpreted within the clinical context, and joint decision-making between patient and provider is important for treatment decisions, especially in ambiguous clinical situations. Expert-led education is needed to assist clinicians with the effective implementation of these strategies into their routine clinical practice.

Target Audience

This activity is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this program, participants should be able to:

  • Review the prognostic significance of cytogenetic and molecular responses to tyrosine kinase inhibitor therapy.
  • Identify goals of therapy and optimal response milestones following tyrosine kinase inhibitor therapy. 
  • Develop an individualized treatment plan integrating patient preference and goals of therapy in appropriate patients with chronic myeloid leukemia (CML).
Additional information
Supporters: 

This activity is supported by educational grants from: 

  • AstraZeneca
  • Daiichi Sankyo 
  • Gilead Sciences, Inc. and Kite, A Gilead Company
  • GlaxoSmithKline
  • Novartis
  • Pfizer Inc.
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Seagen Inc. (formerly Seattle Genetics, Inc.)
  • Takeda

This activity is supported by independent medical education grants from:

  • ADC Therapeutics
  • Bristol Myers Squibb
  • MorphoSys
  • Pharmacyclics LLC and Janssen and Jazz Pharmaceuticals

This educational activity is supported by a medical education grant from Karyopharm® Therapeutics.

This activity is supported by an independent educational grant from Merck & Co., Inc.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
12/15/2021
Course expires: 
12/15/2022
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2021 Virtual Congress: Hematologic Malignancies™

Moderator:

B. Douglas Smith, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Presenters:

Daniel J. DeAngelo, MD, PhD
Dana-Farber Cancer Institute

Neil P. Shah, MD, PhD
UCSF Helen Diller Family Comprehensive Cancer Center

 

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Daniel J. DeAngelo, MD, PhD
AbbVie, Inc.: Grant/Research Support
Amgen Inc.: Consulting Fee
Blueprint Medicines: Grant/Research Support
GlycoMimetics, Inc.: Grant/Research Support
Jazz Pharmaceuticals Inc.: Consulting Fee
Kite Pharma: Consulting Fee
Pfizer Inc.: Consulting Fee

Neil P. Shah, MD, PhD
Bristol-Myers Squibb Company: Grant/Research Support
Taiho Pharmaceuticals Co., Ltd.: Honoraria

B. Douglas Smith, MD
Bristol-Myers Squibb Company: Consulting Fee
Celgene Corporation: Consulting Fee
Celularity Inc.: Consulting Fee
Jubilant Pharma: Scientific Advisor
Novartis Pharmaceuticals Corporation: Consulting Fee
Pfizer Inc.: Consulting Fee

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-21-115-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until December 15, 2022. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing